POWER: Real World Data of 1st line panitumumab treatment in combination with chemotherapy in non resectable wild type (WT) RAS metastatic colorectal cancer (mCRC) subjects in Austria, Bulgaria, Croatia, Czech Republic, Hungary, Poland, Slovenia, Romania, Russia, Greece an Observational Ambidirectional Study (20170734)

Study identification

• EU PAS number:
  EUPAS26499
• Study ID:
  48889
• Official title and acronym:
  POWER: Real World Data of 1st line panitumumab treatment in combination with chemotherapy in non resectable wild type (WT) RAS metastatic colorectal cancer (mCRC) subjects in Austria, Bulgaria, Croatia, Czech Republic, Hungary, Poland, Slovenia, Romania, Russia, Greece an Observational Ambidirectional Study (20170734)
• DARWIN EU® study:
  No
• Study countries:
  Austria

  Bulgaria

  Croatia

  Greece

  Hungary

  Poland

  Romania

  Russian Federation

  Slovenia
• Study description:
  To obtain characteristics of subjects with WT RAS non resectable mCRC receiving panitumumab in combination with chemotherapy as a 1st line treatment, and to describe the patterns of treatment, including 1st and 2nd line therapies
• Study status:
  Finalised

Research institutions and networks

Institutions

Amgen

United States

Study timelines

Date when funding contract was signed

Planned: 01/05/2018

Actual: 01/05/2018

Study start date

Planned: 16/11/2018

Actual: 20/11/2018

Data analysis start date

Planned: 15/03/2022

Actual: 22/11/2021

Date of final study report

Planned: 22/11/2022

Actual: 24/08/2022

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Amgen

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable